$6.93
3.35% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
VGG7185A1286
Symbol
PRTG
Sector
Industry

Portage Biotech Inc Stock price

$6.93
+0.54 8.45% 1M
-3.87 35.83% 6M
-29.47 80.96% YTD
-38.47 84.74% 1Y
-416.27 98.36% 3Y
-193.07 96.54% 5Y
-273.07 97.53% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.24 3.35%
ISIN
VGG7185A1286
Symbol
PRTG
Sector
Industry

Key metrics

Market capitalization $4.78m
Enterprise Value $790.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.99
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-16.09m
Free Cash Flow (TTM) Free Cash Flow $-12.53m
Cash position $3.33m
EPS (TTM) EPS $-70.22
P/E forward negative
Short interest 6.71%
Show more

Is Portage Biotech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Portage Biotech Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Portage Biotech Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Portage Biotech Inc:

Hold
100%

Financial data from Portage Biotech Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
400% 400%
-
-0.05 -0.05
400% 400%
-
- Selling and Administrative Expenses 5.78 5.78
23% 23%
-
- Research and Development Expense 10 10
2% 2%
-
-16 -16
8% 8%
-
- Depreciation and Amortization 0.05 0.05
400% 400%
-
EBIT (Operating Income) EBIT -16 -16
8% 8%
-
Net Profit -71 -71
35% 35%
-

In millions USD.

Don't miss a Thing! We will send you all news about Portage Biotech Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Portage Biotech Inc Stock News

Neutral
GlobeNewsWire
6 months ago
WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.
Neutral
GlobeNewsWire
6 months ago
Company generated approximately $2.8M of non-dilutive funding to extend cash runway Company generated approximately $2.8M of non-dilutive funding to extend cash runway
Neutral
GlobeNewsWire
7 months ago
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Company focused on adenosine platform clinical development
More Portage Biotech Inc News

Company Profile

Portage Biotech, Inc. is a biotechnology company, which enables research and development to produce clinical programs and maximize potential returns. Its portfolio includes subsidiary companies, whose products or technologies have established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. The firm provides funding, strategic business and clinical counsel, and shared services to treat different types of cancers. The company was founded by Gregory H. Bailey in 1973 and is headquartered in Road Town, British Virgin Islands.

Head office Virgin Islands, British
CEO Ian Walters
Employees 7
Founded 1973
Website www.portagebiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today